Research ArticleMetabolism, Transport, and Pharmacogenomics
Open Access
Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin and Amin Rostami-Hodjegan
Journal of Pharmacology and Experimental Therapeutics March 2017, 360 (3) 484-495; DOI: https://doi.org/10.1124/jpet.116.237438
Daniel Scotcher
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
Christopher R. Jones
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
Aleksandra Galetin
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
Amin Rostami-Hodjegan
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMetabolism, Transport, and Pharmacogenomics
PBPK Kidney Model of Digoxin and Renal Impairment
Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin and Amin Rostami-Hodjegan
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 484-495; DOI: https://doi.org/10.1124/jpet.116.237438
Research ArticleMetabolism, Transport, and Pharmacogenomics
PBPK Kidney Model of Digoxin and Renal Impairment
Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin and Amin Rostami-Hodjegan
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 484-495; DOI: https://doi.org/10.1124/jpet.116.237438